Compare Merck & Co., Inc. (MRK) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Schwab US Dividend Equity ETF — how do they compare? Merck & Co., Inc. trades at $142.3 (market cap $352.29B), while Schwab US Dividend Equity ETF trades at $33.09 (market cap $108.68B). The key difference: Merck & Co., Inc. is far larger — about 3.2× Schwab US Dividend Equity ETF's market cap, and Merck & Co., Inc. pays a 2.38% dividend while Schwab US Dividend Equity ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Schwab US Dividend Equity ETF for 62 Days on average.
| MRK | SCHD | |
|---|---|---|
Market Cap | $352.29B | $108.68B |
Volume | 6,348,796 | 21,463,071 |
Sector | Health | Broad Market / Factor |
52-Week High | $156.43 | $35.21 |
52-Week Low | $82.49 | $26.44 |
Typical Hold Time | 98 Days | 62 Days |
Enterprise Value | $399.05B | — |
Dividend Yield | 2.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.79, up 0.61% today, with a bearish technical signal but strong fundamental performance. The company reported revenue of $65.01B in 2025 with a net income margin of 28.07%, and recent quarterly EPS have consistently beaten expectations. Merck is actively expanding its pipeline through acquisitions, such as the pending $6.7B purchase of Terns Pharmaceuticals announced in April 2026.
The outlook is supported by solid profitability and analyst optimism, with a consensus price target of $158.78 implying upside. Key risks include integration challenges from acquisitions and competitive pressures in the oncology sector. Cash flow trends show variability, with a projected net cash outflow of $1.2B in 2026 due to significant investing activities.
SCHD trades at $32.65, down 0.61% on the day, with a bearish technical signal driven by moving averages. The ETF has outperformed the S&P 500 in 2026, with dividend growth attracting income investors. Recent news highlights its defensive tilt and quality focus amid a market pullback.
Outlook is mixed: strong dividend appeal and low fees support long-term income, but technical weakness and interest rate sensitivity pose near-term risks. Investors should weigh SCHD's consistent payout growth against potential underperformance in rising rate environments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →
